News & Updates
Showing Respirology articles
Showing
VV116 noninferior to nirmatrelvir-ritonavir for COVID-19
Early administration of oral VV116 was noninferior to nirmatrelvir-ritonavir in shortening the time to sustained clinical recovery in individuals with mild-to-moderate COVID-19 who were at high risk for progression to severe disease, a phase III trial has shown. VV116 also had fewer safety issues than nirmatrelvir-ritonavir.
Gefitinib plus chemotherapy improves survival outcomes in mutated NSCLC brain metastases
Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.
Childhood asthma, T1D, IBD: Do they have shared mechanisms?
Children diagnosed with asthma between ages 5 and 7 years may have an increased risk of developing type 1 diabetes (T1D) and inflammatory bowel diseases (IBD; Crohn’s disease and ulcerative colitis), a Danish nationwide registry study suggests.
Risk model-based lung cancer screening more economical than USPSTF recommendation
Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.
Shorter treatment regimen feasible for rifampin-resistant TB?
Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.
